Related Experiment Video
Updated: Mar 29, 2026
09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
10.1K
Causal relationship between genetically predicted Enzyme and Tinnitus risk: a two-sample bi-directional mendelian
Peng Liu1, Xinmiao Xue2, Zhixin Zhang2
1Bethune International Peace Hospital, Department of Otolaryngology Head and Neck Surgery, Shijiazhuang, Hebei Province, P.R. China.
Brazilian Journal of Otorhinolaryngology
|March 27, 2026
Summary
This study used Mendelian randomization to find causal links between enzymes and tinnitus. Nine enzymes may cause tinnitus, and tinnitus may affect six enzyme types, offering potential treatment targets.
Area of Science:
- Genetics and Molecular Biology
- Otolaryngology
- Biochemistry
Background:
- Observational studies suggest a link between enzymes and tinnitus.
- The causal relationship between enzymes and tinnitus is not well understood.
Purpose of the Study:
- To investigate the causal relationship between enzymes and tinnitus risk using bi-directional Mendelian randomization.
- To identify potential enzymatic targets for tinnitus treatment.
Main Methods:
- Utilized two-sample bi-directional Mendelian randomization.
- Employed publicly available GWAS summary statistics.
- Applied inverse variance weighted method and sensitivity tests for validity.
Main Results:
- Found suggestive evidence for nine enzymes causally influencing tinnitus.
- Identified causal effects of tinnitus on six enzyme types.
- Included enzymes like HMG-CoA reductase and alanine transaminase.
Conclusions:
- Specific enzymes have a causative effect on tinnitus.
- Reverse causality exists between tinnitus and certain enzymes.
- Findings may lead to new tinnitus treatment strategies.
Related Concept Videos
01:20Gene-Environment Interactions
1.6K
Gene expression is a dynamic process that is significantly influenced by environmental factors. This interaction underlies the complex nature of biological development and the phenotypic differences observed among individuals, even among those with identical genetic makeups. Factors such as radiation, temperature, behavior, nutrition, and stress play pivotal roles in determining how genes are expressed. The concept of the reaction range is central to understanding this interaction. It posits...
1.6K
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
155
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
155
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
61
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
61
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:19Allosteric Proteins-ATCase
6.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.9K